Why the study?
Does vorapaxar added to standard of care therapy reduce major cardiovascular events or death in patients with prior myocardial infarction?
Does vorapaxar added to standard of care therapy reduce major cardiovascular events or death in patients with prior myocardial infarction?
Vorapaxar is a novel antiplatelet agent that may provide additional cardiovascular risk reduction when added to standard therapy in patients with prior myocardial infarction.
May support vorapaxar addition for high-risk post-MI patients; leaves open optimal selection and bleeding trade-offs.
Patients receiving therapy for the secondary prevention of myocardial infarction (MI) are still at high risk of a major cardiovascular event or death despite the use of currently available treatment strategy. Vorapaxar, an oral protease-activated receptor antagonist, is a novel antiplatelet drug that has been recently approved to provide further risk reduction. The results of two Phase III trials (thrombin receptor antagonists for clinical event reduction and the TRA 2°P-TIMI 50) have showed that vorapaxar, in addition to standard of care therapy, has the potential to provide further risk reduction in patients with prior MI. A search was made on PubMed on articles related to clinical trials and clinical consideration with the use of vorapaxar. This review article summarizes the results of Phase II trials, Phase III trials, subgroup analysis, precautions, and drug interaction with the use of vorapaxar.
No takes yet. Share an insight, caveat, or question.
Rotimi et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: